Medication info
Telastat Tablet 80/5 mg

Telastat Tablet 80/5 mg

Prescription medicationOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Aprogen Biologics Co., Ltd.
Appearance
A double-coated oval tablet that is white to light yellow and light blue, biconvex on both sides.
Packaging
10 tablets/PTP x 3
Approval status
Active

MFDS item code 201605852 · Approved 2016.09.30 · Insurance code 645209270

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended that the tablet be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as follows, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended that treatment be initiated at a low dose and the dose increased gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older patients: The usual amlodipine regimen is recommended for older patients, but caution should be exercised when increasing the dose (see section ‘3. Patients Requiring Caution’). Since amlodipine clearance is reduced in patients aged 75 years or older, treatment should be initiated at a low dose and the dose increased gradually.
Child dose
○ Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients aged 18 years or younger; therefore, its use is not recommended.

Ingredients

Manufacturer
Aprogen Biologics Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or telmisartan. It effectively controls blood pressure, reducing the risk of complications.

How to take

Adult dose

The recommended dose is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended that the tablet be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as follows, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended that treatment be initiated at a low dose and the dose increased gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older patients: The usual amlodipine regimen is recommended for older patients, but caution should be exercised when increasing the dose (see section ‘3. Patients Requiring Caution’). Since amlodipine clearance is reduced in patients aged 75 years or older, treatment should be initiated at a low dose and the dose increased gradually.

Child dose

○ Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients aged 18 years or younger; therefore, its use is not recommended.

Precautions

This medication should not be used during pregnancy, especially in the second and third trimesters, as it can pose serious risks to the fetus. If pregnancy is confirmed, this medication should be discontinued as soon as possible. This medication should not be administered to patients with certain diseases or conditions. For example, it should be avoided by individuals who are allergic to this medication, pregnant or breastfeeding women, and those with severely impaired liver or heart function. Patients with impaired liver or kidney function, certain heart valve diseases, and the elderly should use this medication cautiously and dosage should be adjusted under medical supervision. When taking this medication, side effects such as dizziness or edema may occur; therefore, if any unusual symptoms appear, it is essential to consult a healthcare professional immediately. Due to its blood pressure-lowering effect, symptoms of hypotension may arise, especially in patients who are deficient in fluid or salt, who should be particularly cautious. This medication can interact with other drugs; therefore, it is crucial to inform healthcare professionals of any other medications being taken. If pregnant or planning to become pregnant, it is recommended to switch to other antihypertensive medications that have established safety. This medication is also not recommended for breastfeeding women, and should not be used during lactation. The safety and effectiveness of this medication in children and adolescents under 18 years old have not been sufficiently established, so its use is not recommended. In case of overdose, severe hypotension, dizziness, heart problems, etc., may occur, necessitating prompt medical attention.

Side effects

  • Dizziness
  • peripheral edema
  • syncope
  • upper respiratory tract infection
  • pharyngitis
  • sinusitis
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
Show 102 more
  • thrombocytopenia
  • eosinophilia
  • leukopenia
  • hypersensitivity
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • hyponatremia
  • hyperglycemia
  • depression
  • insomnia
  • mood changes
  • anxiety
  • confusion
  • drowsiness
  • headache
  • migraine
  • sensory disturbances
  • sensory loss
  • taste disturbances
  • tremors
  • extrapyramidal disorders
  • muscular hypertonia
  • visual disturbances
  • diplopia
  • vertigo
  • tinnitus
  • palpitations
  • bradycardia
  • tachycardia
  • myocardial infarction
  • ventricular tachycardia
  • arrhythmia
  • atrial fibrillation
  • flushing
  • hypotension
  • orthostatic hypotension
  • vasculitis
  • cough
  • dyspnea
  • rhinitis
  • changes in bowel habits
  • diarrhea
  • constipation
  • abdominal pain
  • dyspepsia
  • nausea
  • pneumatosis intestinalis
  • vomiting
  • dry mouth
  • gingival hyperplasia
  • abdominal discomfort
  • pancreatitis
  • gastritis
  • liver function abnormalities
  • liver damage
  • hepatitis
  • jaundice
  • increased liver enzymes
  • pruritus
  • hyperhidrosis
  • rash
  • alopecia
  • purpura
  • skin discoloration
  • eczema
  • erythema
  • angioedema
  • toxic skin rash
  • drug rash
  • urticaria
  • erythema multiforme
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • joint swelling
  • muscle cramps
  • arthralgia
  • myalgia
  • low back pain
  • limb pain
  • tendon pain
  • renal dysfunction
  • urinary disorders
  • polyuria
  • nocturia
  • erectile dysfunction
  • gynecomastia
  • edema
  • weakness
  • fatigue
  • chest pain
  • malaise
  • influenza-like illness
  • increased liver enzymes
  • increased blood creatinine
  • weight gain
  • weight loss
  • increased blood uric acid
  • increased blood creatine phosphokinase
  • decreased hemoglobin
  • intestinal vascular edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that avoids exposure to light, ideally at room temperature between 1°C and 30°C. This will help maintain the effectiveness of the medication and ensure it can be used safely.

Appearance and packaging

Appearance

A double-coated oval tablet that is white to light yellow and light blue, biconvex on both sides.

Package unit

10 tablets/PTP x 3

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.